Kintor
Kintor
Kintor

About Us

We focus on dermatology and oncology with substantial unmet medical needs,especially androgen receptor-related diseases,

including alopecia, acne, prostate cancer, liver cancer and other conditions that lack effective treatments. Our diverse product pipeline is built on a foundation of internal research and development, supplemented with licensed products. We are committed to developing the best therapeutics to improve human health.

Picture Name

Small-molecule drugs

Kintor Pharma focuses on dermatology and oncology. Our expanded pipeline now includes AR degraders, AR-PROTAC, mTOR inhibitor, Hedgehog inhibitor, and cMyc inhibitor.

Innovative biologics

Kintor Pharma's first biologic drug is an ALK-1 antibody expected to become a "first-in-class" treatment for multiple cancers. 

Combination therapies

To provide the best treatment for prostate and liver cancers and other diseases, Kintor Pharma is creating a diverse pipeline of combination therapies leveraging our innovative drugs.

Our Platforms

Picture Name

R&D Platform

Kintor Pharmaceuticals has established a globally integrated R&D platform that includes a……

Picture Name
Picture Name

Manufacturing base

 Kintor Pharmaceuticals has developed a modern GMP-certified pharmaceutical manufacturing bas……

Picture Name
Picture Name

Business operation

 In anticipation of the commercial launch of our products, Kintor……

Picture Name

News Center

2026-01-22

Exclusive Sales Agency Agreement In Relation To Anti-Hair Loss Foam Product

Suzhou, 21 January, 2026-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that Koshine Hong Kong Limited (the “Koshine Hong Kong”), a wholly-owned subsidiary of the Company, entered into an exclusive sales agency agreement (the “Sales Agency Agreement”) with Beijing Dekai Pharmaceutical Technology Co., Ltd* (北京德開醫藥科技有限公司) (the “Dekai Pharmaceutical”) in relation to the sales agency and market promotion (the “Business Cooperation”) of the Company’s anti-hair loss foam product in the Chinese Mainland market.
Picture Name

2025-09-09

Completion Of Enrollment Of Subjects In Long-Term Human Safety Trial Of KT-939

Suzhou, 9 September, 2025-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that the Company has recently completed the enrollment of 130 subjects for the long-term human safety trial (the “Long-Term Safety Trial”) of KT-939, an in-house developed novel and highly effective tyrosinase inhibitor for inhibiting the melanin production. KT-939 precisely targets tyrosinase and effectively blocks the oxidation process of tyrosine, thereby effectively inhibiting melanin production with antioxidant and anti-inflammatory effects, which demonstrates outstanding advantages in both efficacy and safety for cosmetic applications.
Picture Name

2025-08-12

Phase II Clinical Trial Of GT20029 Gel For The Treatment Of Acne In China Reached Primary Endpoint

Suzhou, 12 August, 2025-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that the Phase II Clinical Trial of its in-house developed androgen receptor (AR) proteolysis targeting chimera (PROTAC) compound GT20029 for the treatment of acne has read out the topline results. Results indicated that the Phase II Clinical Trial has successfully met the primary study endpoint with statistically significant and clinically meaningful outcomes, demonstrating excellent efficacy, safety and pharmacokinetics.
Picture Name
View more
Picture Name

Work at Kintor

We're developing new products to improve human health,and we're looking for people like you to help shape the future at Kintor Pharmaceuticals.We're building a company based on curiosity, talent, and intellectual capital. We provide employees with opportunities for career development and personal growth.lf you're interested  in joining our team, please send your CV to kintor- HR@kintor. com. cn.

Join Us

Kintor